Introduction
============

The World Health Organization (WHO) reviewed the literature on secondary nonadherence to chronic disease prescription medications and concluded the following: 1) medications do not work if patients do not take them, 2) medication nonadherence is a worldwide problem that crosses all jurisdictions, 3) the prevalence of medication nonadherence is of striking magnitude, and 4) this complex issue should be an urgent priority for policy makers and health care providers.[@b1-ppa-12-721] The analysis from the WHO was restricted to secondary nonadherence (patient quits taking medications after starting medical therapy).

Primary nonadherence occurs when a patient consults with a medical doctor, receives a referral for medical therapy, but never fills the first dispensation for the prescription medication.[@b2-ppa-12-721] There are few articles published in the medical literature on primary nonadherence to prescription medications.[@b1-ppa-12-721] For example, in the province of Saskatchewan, Canada, the Health Quality Council concluded that only 29% of patients fill prescriptions for statin medications within 90 days of being hospitalized for a heart attack.[@b3-ppa-12-721]

The impact of medication nonadherence is significant. A research article from Canada demonstrated that 5.4% of all hospitalizations were due to medication nonadherence and that the subsequent total annual cost burden is as high as \$1.6 billion Canadian dollars.[@b4-ppa-12-721] Estimates from a study in the USA suggest that nonadherence to chronic disease medications cost the health care system \$290 billion American dollars every year.[@b5-ppa-12-721],[@b6-ppa-12-721] Besides the cost implications, the impact to human health and quality of life could be enormous. Medication nonadherence is of paramount concern as current evidence suggests that placing an emphasis on efforts to address this important issue could potentially save more lives than discovering new medical innovations to tackle the conditions for which these medications are prescribed.[@b7-ppa-12-721],[@b8-ppa-12-721]

Global improvements in care and prolonged life expectancy have led not only to an increase in the burden of chronic diseases but also a consequent rise in the number of medication prescriptions and increased budgetary spending on chronic diseases.[@b9-ppa-12-721] Chronic conditions such as hypertension, diabetes, and hyperlipidemia are among the predominant chronic conditions, and these ailments contribute directly and indirectly to 68% of all deaths worldwide.[@b10-ppa-12-721] Though not commonly categorized as a chronic condition, depression is the most disabling condition worldwide, contributing significantly to disease and medication prescription burden.[@b11-ppa-12-721]

Clearly, addressing the issues concerning medication nonadherence can have far-reaching implications toward improving the health and well-being of individuals and entire populations. The amount of research work published on primary medication nonadherence (PMNA) is varied with wide-ranging estimates of the effect size.[@b3-ppa-12-721],[@b12-ppa-12-721]--[@b17-ppa-12-721] As such, this study seeks to obtain a pooled estimate of the impact of primary nonadherence to chronic disease medications and identify factors that might be contributing to this important issue.

Materials and methods
=====================

Data sources and study selection
--------------------------------

This study sought to determine the PMNA rate to four common chronic disease medications. The four medication categories considered were antihypertensives, lipid-lowering agents, hypoglycemics, and antidepressants.

PMNA was determined in one of two ways: 1) the proportion of participants who failed to pick up a medication prescribed by their health professional (patient level of measurement) or 2) the proportion of all prescriptions that were not picked up within a specified time (prescription level of measurement).[@b18-ppa-12-721] Measurements made at the patient level can over- or underestimate the true PMNA, which is typically much closer to measurements made at the prescription level.[@b19-ppa-12-721]

We conducted an extensive systematic search of the following electronic databases: Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane central, Embase, MEDLINE, ProQuest, PsycINFO, PubMed, and Scopus. Our search was conducted using a combination of several keywords outlined in the search strategy for each database searched ([Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=161151.pdf)).

In determining the articles to be included in this study, the authors first eliminated duplicates using the EndNote reference management software. The remaining articles were then screened by their titles and abstracts for relevance. Afterward, two of the authors (CN and ML) reviewed the full-text articles independently for relevance and agreement with the predetermined inclusion criteria ([Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=161151.pdf)) to obtain the final articles to be included for the analysis. Methodologic quality and the risk of bias were also independently assessed by two reviewers (CN and ML) by using an adaptation of the Cochrane risk-of-bias tool[@b20-ppa-12-721] and a modified version of the Newcastle-Ottawa scale.[@b21-ppa-12-721] Any disagreements between the reviewing authors (CN and ML) were further discussed and deliberated upon for a possible resolution, and when an agreement was still not possible, a tie-breaking vote was cast by the final author (JM).

Data extraction
---------------

PMNA rates alongside the total number of participants (n) in each study were extracted from each of the included studies. Other relevant information extracted from each study included the type of medication prescribed, the duration of follow-up or observation, the study design, whether the data were from large administrative databases or smaller hospital databases, the average age of study participants, the study location, and the presence or absence of social support (which was defined as some form of routine contact between the health care professional and the participants either through regular follow-ups, text messages, or calls; with the principal aim of improving medication adherence).

Data analysis
-------------

The 95% CI of the included studies was determined using the extracted proportions and the sample size (n). The pooled estimate was obtained using a random-effects model to account for clinical heterogeneity. Heterogeneity was statistically assessed using Higgins I-squared[@b22-ppa-12-721] and further explored with the aid of a subgroup analysis based on categorizations determined a priori. An influence analysis using Tobias' method[@b23-ppa-12-721] was carried out to ascertain the robustness and effect each individual study had on the overall pooled estimate. This involved re-estimating the pooled effect with each study omitted in turn and then assessing whether the overall estimate was skewed significantly. Publication bias was assessed statistically using Begg's test.[@b24-ppa-12-721] All analyses used the "metaprop_one" command and were performed with STATA version 13.1.

Results
=======

Study selection
---------------

A total of 1,492 articles were obtained from the initial search and this was narrowed to 959 articles after deduplication by use of the reference management software. Of the remaining studies, 894 were found to be unrelated to our study and, therefore, removed after careful screening by their titles and abstracts. Guided by the inclusion and exclusion criteria determined a priori, complete copies of the 65 remaining articles were obtained and further screened for relevance. After reviewing the full articles, 24 studies[@b3-ppa-12-721],[@b12-ppa-12-721],[@b14-ppa-12-721]--[@b16-ppa-12-721],[@b19-ppa-12-721],[@b25-ppa-12-721]--[@b42-ppa-12-721] were deemed appropriate for inclusion and underwent risk-of-bias assessment and further analysis ([Figure 1](#f1-ppa-12-721){ref-type="fig"}). A detailed description of the studies included is provided in [Table 1](#t1-ppa-12-721){ref-type="table"}.

Risk-of-bias assessment
-----------------------

Of the selected final 24 articles, 13 were determined to have a low risk of bias, eight were unclear, and three had a high risk of bias. The main methodology concerns among the included experimental studies were centered on performance bias (besides the intervention of interest, researchers acted or treated participants in control or treatment group differently) and detection bias (systematic differences in the measurement of the outcome across both groups). The strengths among the experimental studies included adequate outcome data at follow-up and proper concealment of participant allocation. For the observational studies included for analysis, selection of the cohort of interest was adequate and there was minimal bias noted with the comparability of the cohorts and assessment of the outcome ([Figure 2A and B](#f2-ppa-12-721){ref-type="fig"}).

Characteristics of the pool
---------------------------

A total of 550,485 prescriptions were pooled from the 24 included studies, with 64,892 of those prescriptions not being redeemed within the defined period ([Table 2](#t2-ppa-12-721){ref-type="table"}). Seventeen of the included studies assessed PMNA by following up 467,483 prescriptions for a 3-month duration or less,[@b15-ppa-12-721],[@b16-ppa-12-721],[@b19-ppa-12-721],[@b25-ppa-12-721],[@b26-ppa-12-721],[@b28-ppa-12-721],[@b29-ppa-12-721],[@b31-ppa-12-721]--[@b39-ppa-12-721],[@b41-ppa-12-721] while seven studies assessed PMNA among 83,002 prescriptions over an extended time-frame (ie, \>3 months).[@b3-ppa-12-721],[@b12-ppa-12-721],[@b14-ppa-12-721],[@b27-ppa-12-721],[@b30-ppa-12-721],[@b40-ppa-12-721],[@b42-ppa-12-721] Eight studies determined PMNA at the level of the prescription.[@b12-ppa-12-721],[@b14-ppa-12-721],[@b16-ppa-12-721],[@b19-ppa-12-721],[@b26-ppa-12-721],[@b34-ppa-12-721],[@b40-ppa-12-721],[@b42-ppa-12-721] The highest number of chronic disease medication prescriptions identified in this study were for antihypertensives (190,658), followed closely by antidepressants (164,542), lipid-lowering medications (149,714), and hypoglycemics (45,571). A majority (16) of the studies were retrospective cohort studies,[@b3-ppa-12-721],[@b12-ppa-12-721],[@b14-ppa-12-721]--[@b16-ppa-12-721],[@b19-ppa-12-721],[@b25-ppa-12-721],[@b26-ppa-12-721],[@b28-ppa-12-721],[@b32-ppa-12-721]--[@b35-ppa-12-721],[@b38-ppa-12-721],[@b39-ppa-12-721],[@b41-ppa-12-721],[@b42-ppa-12-721] while seven studies were either prospective cohorts or clinical trials.[@b27-ppa-12-721],[@b29-ppa-12-721]--[@b31-ppa-12-721],[@b36-ppa-12-721],[@b37-ppa-12-721],[@b40-ppa-12-721] Six of the included studies were conducted in Europe,[@b14-ppa-12-721],[@b19-ppa-12-721],[@b26-ppa-12-721],[@b30-ppa-12-721],[@b32-ppa-12-721],[@b33-ppa-12-721] while the rest were in either the United States or Canada.[@b3-ppa-12-721],[@b12-ppa-12-721],[@b15-ppa-12-721],[@b16-ppa-12-721],[@b25-ppa-12-721],[@b27-ppa-12-721]--[@b29-ppa-12-721],[@b31-ppa-12-721],[@b34-ppa-12-721]--[@b36-ppa-12-721],[@b37-ppa-12-721]--[@b42-ppa-12-721] All but seven of the studies utilized data from large administrative databases[@b9-ppa-12-721],[@b14-ppa-12-721]--[@b16-ppa-12-721],[@b19-ppa-12-721],[@b25-ppa-12-721],[@b26-ppa-12-721],[@b28-ppa-12-721],[@b29-ppa-12-721],[@b32-ppa-12-721],[@b34-ppa-12-721],[@b35-ppa-12-721],[@b37-ppa-12-721]--[@b39-ppa-12-721],[@b41-ppa-12-721],[@b42-ppa-12-721] ([Table 3](#t3-ppa-12-721){ref-type="table"}).

Pooled analyses
---------------

Overall, the pooled estimates showed that the incidence of PMNA for the four most common chronic diseases was 14.6% (95% CI: 13.1%--16.2%) ([Table 1](#t1-ppa-12-721){ref-type="table"}; [Figure 3](#f3-ppa-12-721){ref-type="fig"}). These estimates were unlikely to be influenced by bias, as PMNA did not differ significantly in the studies with a low risk of bias when compared to those with an unclear or high risk of bias ([Table 3](#t3-ppa-12-721){ref-type="table"}). Variation between the studies was addressed using a random-effects model and a subgroup analysis was carried out to further explore the potential reasons for between-study variations.

The following findings were of interest. The only sociodemographic variable with a consistent association with PMNA was lack of social support. Those without social support had higher rates of PMNA (20%; 95% CI: 14.4%--26.6%) than those with social support (13.1%; 95% CI: 11.4%--14.8%). Other variables, like age, demonstrated inconsistent associations. PMNA for lipid-lowering medications like statins (20.8%; 95% CI: 16.0%--25.6%) was higher than the PMNA rates for antihypertensives (12.4%; 95% CI: 9.5%--15.3%), hypoglycemics (13.2%; 95% CI: 9.6%--16.8%), and antidepressants (10.8%; 95% CI: 8.2%--13.4%). The extent of PMNA for North America (17.0%; 95% CI: 14.4%--19.5%) was twice the rate estimated for Europe (8.5%; 95% CI: 7.1%--9.9%). Another significant finding was that studies with prescription follow-up lasting \>3 months (25.3%; 95% CI: 19.7%--30.9%) had more than twice the PMNA, compared to those where the studies follow patients for 3 months or less (10.0%; 95% CI: 8.7%--11.4%). Where prospective cohort study designs or clinical trials were used, PMNA was higher, but not significant, compared to retrospective cohort studies. Similarly, PMNA was higher for studies obtained from hospital databases compared to those from large administrative databases but the association was not significant ([Table 3](#t3-ppa-12-721){ref-type="table"}).

Influential analyses carried out following Tobias' method showed that the pooled estimates did not vary significantly with the exclusion of any one study. This suggests that none of the studies had a significant influential effect on the overall estimates ([Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=161151.pdf)). Publication bias was assessed statistically using Begg's test. The test was not statistically significant (adjusted Kendall's score=208, *P*=0.066), suggesting that publication bias was unlikely.

Discussion
==========

The WHO has identified the issue of medication nonadherence as a global concern and one that requires urgent intervention.[@b1-ppa-12-721] In our meta-analysis, we found that on average 15 of every 100 medications prescribed for chronic diseases or conditions are not initially filled by patients. Cost barriers play a key role in promoting medication non-adherence.[@b43-ppa-12-721]

For secondary nonadherence to chronic disease medications, two meta-analyses reviewed nonadherence to statins (49.0%; 95% CI: 48.9%--49.2%) and antihypertensive medications (48.5%; 95% CI: 47.7%--49.2%) in real-world settings.[@b2-ppa-12-721],[@b44-ppa-12-721] If we put together the findings from these two meta-analyses on secondary nonadherence, along with the findings from our meta-analysis that showed primary nonadherence of 14.6%, we can extrapolate that \~41.8% of patients are adherent to chronic disease or chronic condition medications (49% of 85.4% equals 41.8%). Placing these figures alongside the cost estimates from the New England Health Institute, one can preliminarily ascertain that if steps were taken to reduce the PMNA rate for chronic disease medications by even 1% (on an absolute level -- not relative) it can potentially save the US health care system \~\$2.9 billion (USD) annually.[@b6-ppa-12-721]

Our subgroup analysis showed that lipid-lowering medications like statins had the highest rate of PMNA for the chronic disease medications (20.8%). A plausible explanation for the observed high PMNA rate is that these medications are often used for primary prevention and, therefore, patients may feel that there is no immediate threat to their health.[@b2-ppa-12-721],[@b45-ppa-12-721] This was not the case with hypoglycemic or antidepressant medications, where the common indications for use have clear morbidity and mortality implications that can be easily recognized by patients.

Additionally, we found a difference between the PMNA rates for chronic disease medications when we stratified by the location of the study. Prescriptions for medications based out of Europe had a PMNA rate of 8.5%, while those from North America had PMNA rates of 17.0%. These differences may be related to the variations in the delivery of care and the cost of health care in these regions. In most cases, European nations have stronger social programs that include universal health care coverage with a greater percentage of public funding.[@b46-ppa-12-721],[@b47-ppa-12-721] On the other hand, the North American studies were predominantly from the USA, where universal coverage is limited and there is greater dependence on private insurance systems.[@b47-ppa-12-721]

Our subgroup analysis by the duration of follow-up showed that PMNA rates for studies with a longer period of follow-up (3 months or more) were more than double the rates for those with shorter follow-up (3 months or less). This is expected, as the longer the study duration, the more likely nonadherence will be detected.[@b27-ppa-12-721] For example, in one study, it took patients an average of \~2 years to fill their first prescription for statin medications.[@b2-ppa-12-721]

The absence of social support was also noted to play a key role in negatively impacting the PMNA rates. These findings are not surprising, as studies in the past have shown a clear relationship between the absence of social support and patient nonadherence.[@b15-ppa-12-721],[@b27-ppa-12-721],[@b29-ppa-12-721],[@b36-ppa-12-721],[@b37-ppa-12-721],[@b48-ppa-12-721],[@b49-ppa-12-721] Given that social support from clinicians, family members, and friends is a modifiable factor, this variable represents an area of interest and further research.

The Cochrane Collaboration reviewed the literature on the impact of social support on medication nonadherence and concluded that more frequent interaction between doctors and patients was the most effective intervention.[@b50-ppa-12-721] A second meta-analysis from the Cochrane Collaboration reviewed interventions to specifically improve adherence to lipid-lowering medications. Overall, only one of four patients continued to take medications in the long term. In this review, patient reinforcement and regular reminders were the most promising interventions. The authors concluded that a combination of strategies including reminders, reinforcement, and emphasis on appreciating the patient's perspective might lead to the most effective strategy.[@b51-ppa-12-721] Similarly, the National Collaborating Centre for Primary Care performed a systematic review of the literature and advocated that health care professionals 1) adapt their consultation style to the needs of individual patients, 2) make information more accessible and easy to understand for their patients, 3) increase patient involvement in decision making, 4) be aware that patients may have concerns about their prescribed medicines, and 5) recognize that nonadherence is quite common and that they should routinely assess for it in a nonjudgmental way.[@b52-ppa-12-721]

In summary, our meta-analysis helps to provide a more clear and accurate picture of the burden of PMNA, while identifying a number of associated factors. Health care professionals and policy makers should place more emphasis on proper medication counseling, patient social support, and clinical follow-up to help reduce PMNA, especially where the indications for the prescribed medication aim to provide primary prevention.

Strengths and limitations
-------------------------

Our study has several strengths. There is a high level of congruence between our findings and those reported in the existing literature. However, our study provides a more clear and accurate picture of the PMNA impact because its reported effect estimates are not influenced by any single study. Additionally, the increased sample size obtained from pooling the effects of the included studies provides statistical strength.

Despite its strengths, our study has a few limitations. Given the nature of our study and its reliance on secondary data, we experienced some challenges in handling the residual (unmeasured) confounding effects that may be present within each study (eg, some of the included studies had identified their inability to assess the attitudes and beliefs of patients toward the prescribed medication, when these factors could clearly affect PMNA). Also, some of the values from the included studies might be either under- or overestimated because there is no way to independently verify whether patients either filled or did not fill their prescriptions from other sources or locations (ie, filled in different pharmacies or different states or provinces). Finally, some of the included studies were carried out with populations that could not be entirely generalizable and, therefore, should be interpreted with some level of caution.
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###### 

Description of included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study and study location                                  Prescribed medication class   Duration of follow-up   Study design   Average/median age (years)                     Database         Level of measurement   Predictors of primary nonadherence
  --------------------------------------------------------- ----------------------------- ----------------------- -------------- ---------------------------------------------- ---------------- ---------------------- ---------------------------------------------------------------------------------------------
  Aznar-Lou et al;[@b26-ppa-12-721] 2017, Spain             Hypoglycemics\                1 month                 R.cohort       52.4                                           Administrative   Prescription           No comorbidities, diseases other than diabetes, young female prescribing GP, GP in training
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering\                                                                                                                                             
                                                            Antidepressants                                                                                                                                             

  Bauer et al;[@b15-ppa-12-721] 2014, USA                   Antidepressants               2 months                R.cohort       58                                             Administrative   Patient                Lack of involvement in decision making

  Casebeer et al;[@b27-ppa-12-721] 2009, USA                Lipid-lowering                4 months                CT             58                                             Hospital         Patient                No social support: absence of educational programs

  Chan et al;[@b3-ppa-12-721] 2004, Canada                  Antihypertensives\            60 months               R.cohort       70                                             Hospital         Patient                --
                                                            Lipid-lowering                                                                                                                                              

  Cheetham et al;[@b28-ppa-12-721] 2013, USA                Lipid-lowering                3 months                R.cohort       57[a](#tfn2-ppa-12-721){ref-type="table-fn"}   Administrative   Patient                Black race, polymedication

  Derose et al;[@b29-ppa-12-721] 2013, USA                  Lipid-lowering                3 months                RCT            56.1                                           Administrative   Patient                No social support: absence of text reminder, no drug coverage

  Ewen et al;[@b30-ppa-12-721] 2015, Germany                Antihypertensives             6 months                P.cohort       62.7                                           Hospital         Patient                --

  Fischer et al;[@b31-ppa-12-721] 2015, USA                 Hypoglycemics\                0.5 months              RCT            53.2                                           Hospital         Patient                --
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering                                                                                                                                              

  Fischer et al;[@b12-ppa-12-721] 2010, USA                 Hypoglycemics\                12 months               R.cohort       44.3                                           Administrative   Prescription           New prescriptions
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering\                                                                                                                                             
                                                            Antidepressants                                                                                                                                             

  Freccero et al;[@b32-ppa-12-721] 2016, Sweden             Antidepressants               1 month                 R.cohort       48.2                                           Administrative   Patient                Country of origin, young age, marital status (divorce)

  van Geffen et al;[@b33-ppa-12-721] 2009, the Netherland   Antidepressants               1 month                 R.cohort       48.5                                           Hospital         Patient                New prescriptions

  Jackevicius et al;[@b34-ppa-12-721] 2008, Canada          Hypoglycemics\                1 month                 R.cohort       76.3                                           Administrative   Prescription           Older age, higher income, more medications
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering\                                                                                                                                             
                                                            Antidepressants                                                                                                                                             

  Karter et al;[@b35-ppa-12-721] 2009, USA                  Hypoglycemics\                2 months                R.cohort       61.2                                           Administrative   Patient                --
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering                                                                                                                                              

  Kerner et al;[@b36-ppa-12-721] 2017, USA                  Antihypertensives             1 month                 P.cohort       63.9                                           Hospital         Patient                No social support: absence of messages and calls

  Linnet et al;[@b19-ppa-12-721] 2012, Iceland              Hypoglycemics\                1 month                 R.cohort       --                                             Administrative   Prescription           Cost
                                                            Antihypertensives\                                                                                                                                          
                                                            Antidepressants                                                                                                                                             

  O'Connor et al;[@b37-ppa-12-721] 2014, USA                Hypoglycemics                 2 months                RCT            61.7                                           Administrative   Patient                No social support: absence of telephone support

  Raebel et al;[@b25-ppa-12-721] 2012, USA                  Hypoglycemics\                1 month                 R.cohort       59.2                                           Administrative   Patient                Race, smoking, less care contacts, comorbidities, cost
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering                                                                                                                                              

  Shah et al;[@b38-ppa-12-721] 2008, USA                    Hypoglycemics                 1 month                 R.cohort       49                                             Administrative   Patient                Cost, good health

  Shah et al;[@b39-ppa-12-721] 2009, USA                    Antihypertensives             1 month                 R.cohort       47                                             Administrative   Patient                Female, comorbidities, older age, less severe disease

  Shin et al;[@b16-ppa-12-721] 2012, USA                    Hypoglycemics\                3 months                R.cohort       46.5                                           Administrative   Prescription           Minority race, lower income, greater number of prescriptions on the index date
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering\                                                                                                                                             
                                                            Antidepressants                                                                                                                                             

  Tamblyn et al;[@b40-ppa-12-721] 2014, Canada              Hypoglycemics\                9 months                P.cohort       61.6                                           Hospital         Prescription           New prescriptions, young age, cost, lower health visits
                                                            Antihypertensives\                                                                                                                                          
                                                            Lipid-lowering                                                                                                                                              

  Thengilsdóttir et al;[@b14-ppa-12-721] 2015, Iceland      Lipid-lowering\               12 months               R.cohort       58.7 45.4                                      Administrative   Prescription           Female gender, cost
                                                            Antidepressants                                                                                                                                             

  Trinacty et al;[@b41-ppa-12-721] 2009, USA                Hypoglycemics                 1 month                 R.cohort       51                                             Administrative   Patient                --

  Xing et al;[@b42-ppa-12-721] 2011, USA                    Antidepressants               24 months               R.cohort       51.5                                           Administrative   Prescription           New prescriptions, young age
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Database: the data source, that is, administrative (from large admin databases), hospital (from clinic or hospital records). Level of measurement: primary nonadherence could have been measured as the proportion of participants (patient level of measurement) failing to fill their prescription or the proportion of prescriptions not filled (prescription level of measurement).

The age obtained from this particular study was a median value (unlike the others which were means).

**Abbreviations:** CT, controlled trial; GP, General Practitioner; PMNA, primary medication nonadherence; P.cohort, prospective cohort; R.cohort, retrospective cohort; RCT, randomized controlled trial.

###### 

Pooled estimates

  Study and study location                                  Prescribed medication class   Number of study prescriptions   Primary nonadherence rate (%)   95% CI
  --------------------------------------------------------- ----------------------------- ------------------------------- ------------------------------- ------------
  Aznar-Lou et al;[@b26-ppa-12-721] 2017, Spain             Hypoglycemics                 8,270                           13.2                            12.5--14.0
  Antihypertensives                                         74,346                        7.5                             7.3--7.7                        
  Lipid-lowering                                            69,602                        8.8                             8.6--9.0                        
  Antidepressants                                           97,635                        11.5                            11.3--11.7                      
  Bauer et al;[@b15-ppa-12-721] 2014, USA                   Antidepressants               1,523                           4.3                             3.3--5.4
  Casebeer et al;[@b27-ppa-12-721] 2009, USA                Lipid-lowering                913                             43.2                            39.9--46.4
  Chan et al;[@b3-ppa-12-721] 2004, Canada                  Antihypertensives             1,700                           33.5                            31.3--35.8
  Lipid-lowering                                            1,700                         71.0                            68.8--73.1                      
  Cheetham et al;[@b28-ppa-12-721] 2013, USA                Lipid-lowering                19,826                          15.4                            14.9--15.9
  Derose et al;[@b29-ppa-12-721] 2013, USA                  Lipid-lowering                5,216                           18.4                            17.4--19.5
  Ewen et al;[@b30-ppa-12-721] 2015, Germany                Antihypertensives             100                             2.0                             0.2--7.0
  Fischer et al;[@b31-ppa-12-721] 2015, USA                 Hypoglycemics                 346                             6.4                             4.0--9.5
  Antihypertensives                                         2,065                         3.3                             2.6--4.2                        
  Lipid-lowering                                            528                           6.4                             4.5--8.9                        
  Fischer et al;[@b12-ppa-12-721] 2010, USA                 Hypoglycemics                 5,525                           21.9                            20.8--23.0
  Antihypertensives                                         30,211                        19.5                            19.0--19.9                      
  Lipid-lowering                                            12,963                        19.9                            19.2--20.6                      
  Antidepressants                                           11,767                        21.4                            20.6--22.1                      
  Freccero et al;[@b32-ppa-12-721] 2016, Sweden             Antidepressants               11,624                          14.9                            14.3--15.6
  van Geffen et al;[@b33-ppa-12-721] 2009, the Netherland   Antidepressants               965                             4.3                             3.1--5.7
  Jackevicius et al;[@b34-ppa-12-721] 2008, Canada          Hypoglycemics                 146                             13.7                            8.6--20.4
  Antihypertensives                                         5,337                         6.4                             5.8--7.1                        
  Lipid-lowering                                            758                           5.2                             3.7--7.0                        
  Antidepressants                                           43                            32.6                            19.1--48.5                      
  Karter et al;[@b35-ppa-12-721] 2009, USA                  Hypoglycemics                 8,191                           4.0                             3.6--4.5
  Antihypertensives                                         12,712                        3.2                             2.9--3.5                        
  Lipid-lowering                                            6,426                         8.5                             7.8--9.2                        
  Kerner et al;[@b36-ppa-12-721] 2017, USA                  Antihypertensives             9                               22.2                            2.8--60.0
  Linnet et al;[@b19-ppa-12-721] 2012, Iceland              Hypoglycemics                 760                             8.7                             6.8--10.9
  Antihypertensives                                         4,127                         8.6                             7.7--9.5                        
  Antidepressants                                           4,492                         6.6                             5.9--7.4                        
  O'Connor et al;[@b37-ppa-12-721] 2014, USA                Hypoglycemics                 2,378                           13.3                            11.9--14.7
  Raebel et al;[@b25-ppa-12-721] 2012, USA                  Hypoglycemics                 1,521                           11.3                            9.8--13.0
  Antihypertensives                                         4,721                         7.0                             6.3--7.8                        
  Lipid-lowering                                            4,607                         12.6                            11.6--13.6                      
  Shah et al;[@b38-ppa-12-721] 2008, USA                    Hypoglycemics                 1,132                           15                              13.0--17.2
  Shah et al;[@b39-ppa-12-721] 2009, USA                    Antihypertensives             3,240                           17.1                            15.8--18.5
  Shin et al;[@b16-ppa-12-721] 2012, USA                    Hypoglycemics                 14,417                          12.6                            12.0--13.1
  Antihypertensives                                         48,982                        7.8                             7.5--8.0                        
  Lipid-lowering                                            22,249                        22.3                            21.8--22.9                      
  Antidepressants                                           27,383                        7.7                             7.4--8.0                        
  Tamblyn et al;[@b40-ppa-12-721] 2014, Canada              Hypoglycemics                 979                             29.1                            26.3--32.1
  Antihypertensives                                         3,108                         32.2                            30.5--33.8                      
  Lipid-lowering                                            2,794                         33.6                            31.9--35.4                      
  Thengilsdóttir et al;[@b14-ppa-12-721] 2015, Iceland      Lipid-lowering                2,132                           6.2                             5.2--7.3
  Antidepressants                                           8,553                         8.0                             7.4--8.6                        
  Trinacty et al;[@b41-ppa-12-721] 2009, USA                Hypoglycemics                 1,906                           10.0                            8.7--11.5
  Xing et al;[@b42-ppa-12-721] 2011, USA                    Antidepressants               557                             13.1                            10.4--16.2
  Pooled random estimate                                                                  550,485                         14.6                            13.1--16.2

###### 

Subgroup analysis

  Subgroup                    PMNA (95% CI)       N
  --------------------------- ------------------- ---------
  Medication                                      
   Hypoglycemics              13.2 (9.6--16.8)    45,571
   Antihypertensives          12.4 (9.5--15.3)    190,658
   Lipid-lowering             20.8 (16.0--25.6)   149,714
   Antidepressants            10.8 (8.2--13.4)    164,542
  Duration of follow-up                           
   ≤3 months                  10.0 (8.7--11.4)    467,483
   \>3 months                 25.3 (19.7--30.9)   83,002
  Study design                                    
   R.cohort                   13.5 (11.8--15.2)   532,049
   P.cohort, CT, RCT          18.9 (11.0--26.8)   18,436
  Average age, years                              
   50 or less                 14.8 (11.4--18.2)   199,011
   51--60                     11.4 (9.8--12.9)    295,714
   \>60                       20.4 (14.9--25.8)   46,381
  Data source                                     
   Administrative database    11.7 (10.2--13.3)   535,278
   Hospital database          24.0 (12.0--35.9)   15,207
  Level of measurement                            
   Prescription               14.5 (12.7--16.4)   457,136
   Patient                    14.8 (11.4--18.2)   93,349
  Risk of bias                                    
   Low risk                   12.9 (11.2--14.5)   493,728
   Unclear/high risk          17.3 (13.0--21.5)   56,757
  Location                                        
   North America              17.0 (14.4--19.5)   267,879
   Europe                     8.5 (7.1--9.9)      282,606
  Absence of social support                       
   Yes                        20.5 (14.4--26.6)   27,769
   No                         13.1 (11.4--14.8)   522,716

**Abbreviations:** CT, controlled trial; N, total number of prescriptions; PMNA, primary medication nonadherence; P.cohort, prospective cohort; RCT, randomized controlled trial; R.cohort, retrospective cohort.
